CiteNote Verification

PACKET IDENTITY

Drug	Tacrolimus
Gestational age	37w0d
Patient stage	Pregnancy
Referring specialty	Not specified
Software generated at	May 25, 2026 at 17:23 UTC
Physician attested at	May 25, 2026 at 17:25 UTC
SHA-256	5aa68ea22187ad2009deda79d7cc7503107604bd0ff232ee433d826e42b23741

PHYSICIAN ATTESTATION

Attesting physician	jane smith
Role	Attending
Software generated at	May 25, 2026 at 17:23 UTC
Physician attested at	May 25, 2026 at 17:25 UTC

Physician attested: “I have reviewed this coordination record and am transmitting these questions to the specialist team.” The attestation timestamp is set server-side at the moment of submission and is covered by the SHA-256 signature above.

CLINICAL QUESTION

peridelivery tacrolimus monitoring protocol and postpartum dose adjustment given expected rise in tacrolimus levels as pregnancy pharmacokinetics reverse in the first 72 hours after delivery

EVIDENCE TIER

PEER-REVIEWED EVIDENCE

CLINICAL CONSTRAINTS

history of orthotopic cardiac transplant in 2019 for dilated cardiomyopathy, tacrolimus trough goal range 5-7 ng/mL per transplant team, most recent tacrolimus trough 7.1 ng/mL drawn 4 days ago, planning delivery at 37-38 weeks

PREGNANCY-SPECIFIC EVIDENCE SUMMARY

PLACENTAL TRANSFER AND FETAL EXPOSURE

The provided evidence does not contain specific data on tacrolimus placental transfer or fetal drug levels. However, the evidence demonstrates that tacrolimus clearance increases significantly during pregnancy, with clearance rising by 15-21% across trimesters (PMID:37596793) and oral clearance being 39% higher during mid and late pregnancy compared to postpartum (PMID:23007747). This pharmacokinetic change necessitates dose increases during pregnancy to maintain therapeutic levels (PMID:26093738).

MATERNAL OUTCOMES

For this patient at 37 weeks with a current tacrolimus trough of 7.1 ng/mL (at the upper boundary of the 5-7 ng/mL goal range), the evidence indicates that tacrolimus clearance will decrease rapidly postpartum, returning from the elevated pregnancy state to baseline levels. Studies show oral clearance decreases by approximately 28% from late pregnancy to postpartum (47.4 vs 34.2 L/h, PMID:23007747), suggesting this patient's levels will rise above the therapeutic range without dose reduction. The constraint of maintaining immunosuppression for cardiac transplant protection requires careful monitoring to prevent both rejection and toxicity during this pharmacokinetic transition.

NEONATAL OUTCOMES

The provided evidence does not contain specific data on neonatal outcomes, monitoring requirements, or toxicity related to in utero tacrolimus exposure. No information is available regarding neonatal tacrolimus levels, clearance, or clinical effects in newborns exposed to tacrolimus during pregnancy. The evidence focuses exclusively on maternal pharmacokinetics without addressing neonatal safety or monitoring protocols.

EVIDENCE GAPS

The specific clinical question regarding peridelivery tacrolimus monitoring protocol and postpartum dose adjustment timing cannot be adequately answered by the available evidence. While the evidence demonstrates that tacrolimus clearance decreases postpartum, it lacks specific guidance on monitoring frequency in the immediate 72-hour postdelivery period, the magnitude and timeline of dose reductions needed, or protocols for patients with cardiac transplants who require precise immunosuppressive levels. The evidence does not address how quickly levels rise postpartum or provide specific monitoring intervals for the peridelivery period.

CARE OWNERSHIP

MFM Manages:

Peripartum tacrolimus level monitoring: draw tacrolimus trough within 24 hours of delivery and again at 48-72 hours postpartum to capture the expected rise as pregnancy pharmacokinetics reverse
Delivery timing coordination: schedule delivery at 37-38 weeks as planned, ensuring transplant team is notified 48 hours before scheduled delivery for final level check and dose adjustment recommendations
Neonatal monitoring coordination: alert neonatology to monitor for hyperkalemia, renal dysfunction, and growth parameters from in utero tacrolimus exposure in first 48 hours of life

Transplant Manages:

Postpartum dose reduction protocol: provide written tacrolimus dose adjustment plan for the first week postpartum as clearance decreases and levels are expected to rise above the 5-7 ng/mL target range
Peripartum rejection surveillance: define the specific clinical and laboratory thresholds for rejection monitoring during the peripartum period when tacrolimus levels may fluctuate
Target trough confirmation: confirm whether the current trough of 7.1 ng/mL at the upper end of the 5-7 ng/mL range requires dose reduction before delivery to prevent supratherapeutic levels postpartum

Shared Responsibilities:

Peripartum medication transition protocol: coordinate timing of postpartum level checks with dose adjustments to maintain therapeutic levels while preventing toxicity as pregnancy pharmacokinetics reverse

SPECIFIC QUESTIONS TO TRANSPLANT:

Given the current tacrolimus trough of 7.1 ng/mL at the upper end of the 5-7 ng/mL target range, should the dose be reduced before delivery to prevent supratherapeutic levels in the first 72 hours postpartum?
What is the specific tacrolimus dose reduction protocol for the first postpartum week — should the dose be reduced by 25%, 50%, or held entirely, and at what trough level should the original dose be resumed?

SOURCES CONSULTED

Lane	Source
PUBMED	PMID:26093738 PMID:26093738
PUBMED	PMID:37596793 PMID:37596793
PUBMED	PMID:31346820 PMID:31346820
PUBMED	PMID:41609230 PMID:41609230
PUBMED	PMID:23007747 PMID:23007747
PUBMED	PMID:9919394 PMID:9919394
PUBMED	PMID:37975160 PMID:37975160
PUBMED	PMID:32959455 PMID:32959455
PUBMED	PMID:30821534 PMID:30821534
PUBMED	PMID:26888948 PMID:26888948
LACTMED	NBK501104
LACTMED	NBK501104
LACTMED	NBK501104
FDA	FDA_LABEL_TACROLIMUS
FDA	FDA_LABEL_TACROLIMUS
PUBMED	PUBMED_23899232 PMID:23899232
PUBMED	PUBMED_23899232 PMID:23899232

EVIDENCE RECENCY

Data recency for LACTMED source is unknown; date of last update could not be determined.
Data for PUBMED source may be older than the recency threshold. source_last_updated 2023-01-01; threshold 36 months; retrieved_at_utc 2026-05-25T17:23:31

Evidence recency flags are disclosed for transparency. They indicate sources that may not reflect the most current published literature at the time of this review. The treating physician is responsible for clinical judgment and for assessing whether additional or more recent evidence should be consulted before acting on this record.

RECORD CLINICAL RESPONSE

This record was generated by CiteNote and sealed at the time shown above. The SHA-256 hash above uniquely identifies this packet. Any modification to the packet contents after signing would produce a different hash and would not match this verified record.